Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Genomic DNA of *Escherichia coli* and *Klebsiella pneumoniae* refers to the complete chromosomal DNA present within each organism. This genetic material encodes all proteins, structural RNAs, regulatory elements, and other sequence features necessary for the survival, replication, and pathogenicity of these bacteria[2][4][5]. The genome consists of both highly conserved core genes (essential for basic cell functions) and accessory genes, including those that may encode virulence factors, antibiotic resistance determinants, and strain-specific attributes[2][5]. The genomes of both species are highly diverse and dynamic, showing frequent acquisition of new genes via horizontal gene transfer, mobile genetic elements, and genetic rearrangements[2][5][7]. These entire genomic DNAs are sometimes utilized in research and diagnostics (for example, as templates for PCR or sequencing[1]), but "genomic DNA" itself is *not* a specific therapeutic target, receptor, enzyme, transporter, or druggable protein. Instead, specific genes, gene clusters, or proteins encoded *within* the genomic DNA may serve as valid therapeutic or diagnostic targets (e.g., beta-lactamase genes for antibiotic resistance, virulence operons, etc.)[1][6]. Therefore, as written, the entity "Genomic DNA of E. coli and K. pneumoniae" is incorrectly formatted and inappropriately broad to be considered a drug target. Key Issues: - The term does not refer to a single molecular entity, receptor, enzyme, or structure that can be engaged by a drug, but rather to all hereditary material of two bacterial species. - There are no standardized abbreviations, aliases, or specific families/classifications for this entirety; it is always referenced contextually, with focus usually on sub-elements or genes of interest[1][2][5]. - It does not have a defined mechanism of action, interact with drugs per se (drugs target gene products), nor is it associated with specific biomarkers or safety concerns in the way proteins or defined biomolecules are. In summary, *genomic DNA of E. coli and K. pneumoniae* is not a therapeutically actionable target and the query likely contains an error in target granularity or specificity. Proper targets require specification at the level of genes, proteins, operons, or molecular pathways encoded by this genomic DNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Genomic DNA of Escherichia coli and Klebsiella pneumoniae.